Arylsulphonyl hydroxamic acids: Potent and selective matrix metalloproteinase inhibitors

被引：21

作者：

Baxter, AD ^{[1
]}

Bhogal, R ^{[1
]}

Bird, J ^{[1
]}

Keily, JF ^{[1
]}

Manallack, DT ^{[1
]}

Montana, JG ^{[1
]}

Owen, DA ^{[1
]}

Pitt, WR ^{[1
]}

Watson, RJ ^{[1
]}

Wills, RE ^{[1
]}

机构：

[1] Celltech Chirosci Ltd, Cambridge CB1 6GS, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 11期

关键词：

D O I：

10.1016/S0960-894X(01)00259-1

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1465 / 1468

页数：4

共 10 条

[1]

Baxter AD, 2000, CANC DRUG DISC DEV, P193

[2]

BIRD J, 1999, GORD RES C MATR MET

[3]

BIRD J, 1998, Patent No. 9839024

[4]

BORKAKOTI N, 1998, METH PRIN MED CHEM, V6, P73

[5] Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold [J].

Cheng, MY ;

De, B ;

Almstead, NG ;

Pikul, S ;

Dowty, ME ;

Dietsch, CR ;

Dunaway, CM ;

Gu, F ;

Hsieh, LC ;

Janusz, MJ ;

Taiwo, YO ;

Natchus, MG ;

Hudlicky, T ;

Mandel, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (26) :5426-5436

[6]

HADJUK PJ, 1997, J AM CHEM SOC, V119, P5818

[7] Clinical potential of matrix metalloprotease inhibitors in cancer therapy [J].

Heath, EI ;

Grochow, LB .

DRUGS, 2000, 59 (05) :1043-1055

[8]

Montana J, 2000, Curr Opin Drug Discov Devel, V3, P353

[9]

SHALINSKY DR, 1999, CURR OPIN ONC END ME, V1, P473

[10] Design and therapeutic application of matrix metalloproteinase inhibitors [J].

Whittaker, M ;

Floyd, CD ;

Brown, P ;

Gearing, AJH .

CHEMICAL REVIEWS, 1999, 99 (09) :2735-2776

← 1 →